Phathom Pharmaceuticals, Inc.
$4.02
-0.21 (-4.96%)
PHAT Price Chart
| Basic | |
|---|---|
| Market Cap | $374.71M |
| Price | $4.02 |
| 52 Week Range | 5.21-19.71 |
| Beta | 0.72 |
| Margins | |
| Gross Profit Margin | 86.23% |
| Operating Profit Margin | -349.84% |
| Net Profit Margin | -307.20% |
| Valuation (TTM) | |
| P/E Ratio | -2.87 |
| Price to Sales Ratio | 8.55 |
| Price to Book Ratio | -2.13 |
| PEG Ratio | -1.40 |
Industry
Biotechnology
Sector
Healthcare
Full-Time Employees
452
IPO Date
2019-10-25T00:00:00.000Z
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phone
877 742 8466
Address
100 Campus Drive, Florham Park, NJ, 07932, US
CIK
0001783183